Roche's Multiple Sclerosis Injection Gets EU Approval
Provided by
Dow Jones
By Adria Calatayud
Roche Holding said its Ocrevus injection for multiple sclerosis got approval in the European Union.
The Swiss pharmaceutical company said Tuesday that the European Commission granted marketing authorization for a subcutaneous version of its Ocrevus injection, adding to the previously approved intravenous infusion. The approval was based on data from a late-stage trial that showed safety and efficacy for the injection was comparable to the intravenous formulation, the company said.
The subcutaneous injection makes it easier for patients to access their treatments, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
June 25, 2024 01:27 ET (05:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations